Will the FDA approve MDMA for PTSD?

Health & MedicineOne-Off5m

KalshiVerifica disponibilitàKYC richiesto2% di commissioneDati di risoluzione verificatiCalibrazione approssimativa

Probabilità implicita attuale

Before Jan 1, 2031 56%

In testa tra 6 esiti

Qualita del mercato

40 / 100

Bassa qualità

Volume 24h

0 €

Liquidità

1,3K €

Bassa liquidità

Bid / Ask

11.0% / 16.0%

Spread

5.0 pt

Spread moderato

Dati di mercato

Aggiornato 15 minuti fa

14 mag 26, 2:001 gen 27, 4:59

Trend

Esito24hProbabilità

Solo fondi simulati, nessun denaro realeNon è consulenza finanziaria

Esito scelto

Before Jan 1, 202710%

Puntata (USDT)

Regole

If the FDA approves midomafetamine / MDMA for PTSD for marketing before Jan 1, 2027, then the market resolves to Yes.

An approval is defined as:
For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application
The following constitute approvals that trigger the Payout Criterion:
Standard approval (traditional approval based on clinical benefit) Accelerated approval (based on surrogate endpoints) Approval with Risk Evaluation and Mitigation Strategy (REMS) Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs
The following do NOT constitute approvals:

Trend del volume

2 lug10g di dati27 lug

Mercati Correlati

Will the FDA approve camizestrant for advanced breast cancer?

47 €

Before Oct 1, 2026: 37%

KALSHI

Hantavirus pandemic in 2026?

91,3K €

Sì: 3%

POLYMARKET

# of views of MrBeast video day 3?

13,5K €

26-27M: 96%

POLYMARKET

Ebola pandemic in 2026?

4,9K €

Sì: 3%

POLYMARKET

Measles cases in 2026?

Pandemic in 2026?

Attivi in questi argomenti

BitcoinBTC$63,434.87-2.83%

EthereumETH$1,877.47-4.43%

SolanaSOL$73.03-4.56%

DogecoinDOGE$0.0701-3.61%

XRPXRP$1.05-4.70%

BNBBNB$565.48-1.37%

Notizie Correlate

NVIDIA BioNeMo Toolkit Accelerates AI-Driven Drug DiscoveryBlockchain.News

OpenAI Launches GeneBench-Pro to Test AI in BiologyBlockchain.News

Google Transfers Open Health Stack to Linux FoundationBlockchain.News

Regole

If the FDA approves midomafetamine / MDMA for PTSD for marketing before Jan 1, 2027, then the market resolves to Yes.

An approval is defined as:
For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application
The following constitute approvals that trigger the Payout Criterion:
Standard approval (traditional approval based on clinical benefit) Accelerated approval (based on surrogate endpoints) Approval with Risk Evaluation and Mitigation Strategy (REMS) Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs
The following do NOT constitute approvals:

Will the FDA approve MDMA for PTSD?

Health & MedicineOne-Off5m

KalshiVerifica disponibilitàKYC richiesto2% di commissioneDati di risoluzione verificatiCalibrazione approssimativa

Probabilità implicita attuale

Before Jan 1, 2031 56%

In testa tra 6 esiti

Qualita del mercato

40 / 100

Bassa qualità

Volume 24h

0 €

Liquidità

1,3K €

Bassa liquidità

Bid / Ask

11.0% / 16.0%

Spread

5.0 pt

Spread moderato

Dati di mercato

Aggiornato 15 minuti fa

14 mag 26, 2:001 gen 27, 4:59

Trend

Esito24hProbabilità

Solo fondi simulati, nessun denaro realeNon è consulenza finanziaria

Esito scelto

Before Jan 1, 202710%

Puntata (USDT)

Regole

If the FDA approves midomafetamine / MDMA for PTSD for marketing before Jan 1, 2027, then the market resolves to Yes.

An approval is defined as:
For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application
The following constitute approvals that trigger the Payout Criterion:
Standard approval (traditional approval based on clinical benefit) Accelerated approval (based on surrogate endpoints) Approval with Risk Evaluation and Mitigation Strategy (REMS) Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs
The following do NOT constitute approvals:

Trend del volume

2 lug10g di dati27 lug

Mercati Correlati

Will the FDA approve camizestrant for advanced breast cancer?

47 €

Before Oct 1, 2026: 37%

KALSHI

Hantavirus pandemic in 2026?

91,3K €

Sì: 3%

POLYMARKET

# of views of MrBeast video day 3?

13,5K €

26-27M: 96%

POLYMARKET

Ebola pandemic in 2026?

4,9K €

Sì: 3%

POLYMARKET

Measles cases in 2026?

Pandemic in 2026?

Attivi in questi argomenti

BitcoinBTC$63,434.87-2.83%

EthereumETH$1,877.47-4.43%

SolanaSOL$73.03-4.56%

DogecoinDOGE$0.0701-3.61%

XRPXRP$1.05-4.70%

BNBBNB$565.48-1.37%

Notizie Correlate

NVIDIA BioNeMo Toolkit Accelerates AI-Driven Drug DiscoveryBlockchain.News

OpenAI Launches GeneBench-Pro to Test AI in BiologyBlockchain.News

Google Transfers Open Health Stack to Linux FoundationBlockchain.News

Regole

If the FDA approves midomafetamine / MDMA for PTSD for marketing before Jan 1, 2027, then the market resolves to Yes.

An approval is defined as:
For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application
The following constitute approvals that trigger the Payout Criterion:
Standard approval (traditional approval based on clinical benefit) Accelerated approval (based on surrogate endpoints) Approval with Risk Evaluation and Mitigation Strategy (REMS) Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs
The following do NOT constitute approvals: